Gilead Sciences

Gilead Sciences is a prominent American biopharmaceutical company headquartered in Foster City, California. Founded in 1987 by Michael L. Riordan, the company has become a global leader in the development of antiviral drugs to treat life-threatening diseases, most notably HIV/AIDS, hepatitis B, and hepatitis C. Its portfolio has expanded significantly to include innovative treatments in oncology and inflammatory diseases, driven by substantial investment in research and development and strategic acquisitions. The company is a component of the NASDAQ-100 and S&P 500 indices, with its therapies reaching millions of patients worldwide.

History

The company was incorporated in June 1987 by Michael L. Riordan, a physician and entrepreneur, with initial venture capital funding. Its early research focused on nucleoside analogues targeting RNA viruses, leading to its first FDA approval in 1996 for Vistide (cidofovir) to treat cytomegalovirus retinitis in AIDS patients. A major turning point came with the 2001 acquisition of NeXstar Pharmaceuticals, which brought the lucrative liposomal drug DaunoXome. The 2006 purchase of Raylo Chemicals in Canada bolstered its active pharmaceutical ingredient manufacturing. Transformative growth was achieved through the $11 billion acquisition of Pharmasset in 2011, which provided the foundation for its blockbuster hepatitis C regimen, Sovaldi (sofosbuvir). Further expansion into oncology was marked by the $21 billion acquisition of Immunomedics in 2020, adding the antibody-drug conjugate Trodelvy.

Products and research

The company's product portfolio is anchored by its virology franchise. In HIV treatment, it developed the first single-tablet regimen, Atripla, followed by successors like Biktarvy and Descovy, which are mainstays of modern antiretroviral therapy. Its hepatitis C cures, including Harvoni and Epclusa, revolutionized treatment for the disease. The COVID-19 pandemic saw the rapid development and EUA of the antiviral Veklury (remdesivir). In oncology, key products include cell therapy Yescarta (axicabtagene ciloleucel) for non-Hodgkin lymphoma, acquired via the purchase of Kite Pharma, and Trodelvy for metastatic triple-negative breast cancer. Research pipelines are focused on advancing long-acting HIV therapeutics, oncolytic virus platforms, and treatments for inflammatory and fibrotic diseases.

Corporate affairs

The company's global headquarters are located in Foster City, California, within the San Francisco Bay Area. Its operational structure includes commercial and research facilities across North America, Europe, and Asia-Pacific. Key leadership has included former Roche executive Daniel O'Day, who became Chairman and CEO in 2019. The company maintains numerous strategic collaborations with academic institutions, including the University of California system, and other biotech firms like Galapagos NV and Arcus Biosciences. It is a major sponsor of global health initiatives, such as the PEPFAR program and the Medicines Patent Pool, to improve access to medicines in developing countries.

Controversies and legal issues

The company has faced significant scrutiny over drug pricing, particularly for its hepatitis C drugs Sovaldi and Harvoni, which drew criticism from the U.S. Senate Finance Committee and payers like the Department of Veterans Affairs. It has been involved in extensive patent litigation with competitors such as Merck & Co. over hepatitis C drug royalties. The 2020 acquisition of Immunomedics was investigated by the SEC regarding trading activities by the seller. Its promotion of the HIV prevention drug Truvada for PrEP has been part of ongoing lawsuits concerning antitrust practices and patent infringement with the CDC. Environmental concerns have also arisen related to waste discharge from its manufacturing sites.

Financial performance

As a publicly traded entity on the NASDAQ under the symbol GILD, the company has reported substantial revenue, historically driven by its virology segment. Peak annual sales exceeded $30 billion following the launch of its hepatitis C portfolio, though revenues later moderated due to market saturation and increased competition. Major acquisitions, including those of Kite Pharma and Immunomedics, involved significant capital expenditure. The company returns capital to shareholders through an active dividend program and share repurchase initiatives. Its financial results are closely watched by analysts from firms like Goldman Sachs and J.P. Morgan, with performance influenced by product launches, generic drug entry, and outcomes from its clinical trial pipelines.

Category:Biotechnology companies of the United States Category:Pharmaceutical companies of the United States Category:Companies listed on the NASDAQ